viral
respiratori
tract
infect
associ
asthma
incept
earli
life
asthma
exacerb
older
children
adult
although
virus
influenc
asthma
incept
poorli
understood
much
research
focus
host
respons
respiratori
virus
virus
promot
host
respons
affect
subsequ
allergen
sensit
exposur
review
focus
innat
interferonmedi
host
respons
respiratori
virus
discuss
summar
avail
evid
respons
impair
suboptim
addit
abil
respiratori
virus
act
synergist
addit
manner
h
pathway
discuss
review
argu
outcom
like
link
discuss
avail
evid
show
reciproc
neg
regul
innat
interferon
h
mediat
renew
interest
antit
h
biolog
propos
rational
particularli
success
control
asthma
exacerb
suggest
way
futur
clinic
studi
could
use
find
direct
evid
hypothesi
j
allergi
clin
immunol
mucin
product
furthermor
cell
tissu
asthmat
patient
respond
infect
delay
suboptim
antivir
respons
exemplifi
delay
defici
product
innat
interferon
although
process
undoubtedli
import
determin
diseas
outcom
one
idea
outcom
link
current
antit
h
biolog
function
reduc
harm
h
inflamm
also
restor
impair
antivir
respons
review
examin
hypothesi
discuss
evid
support
impair
interferon
product
asthmat
patient
also
impair
interferon
product
could
caus
least
part
increas
h
pathway
allerg
inflamm
simplic
group
allerg
inflamm
h
pathway
togeth
although
accept
h
cytokin
might
made
might
function
independ
allergen
exposur
review
limit
discuss
impair
innat
type
ifnaifnb
type
iii
ifnl
interferon
asthmat
patient
studi
shown
defect
impair
type
ii
ifng
respons
cell
asthmat
patient
lower
h
h
ratio
atop
asthmat
patient
versu
control
subject
howev
studi
discuss
addit
review
focu
discuss
role
innat
interferon
patient
establish
glossari
chemokin
also
known
rant
shown
chemotact
cell
eosinophil
basophil
play
activ
role
recruit
leukocyt
inflammatori
site
help
particular
cytokin
releas
cell
also
induc
prolifer
activ
certain
natur
killer
cell
form
cc
chemokineactiv
killer
chak
cell
also
shown
hivsuppress
factor
releas
cell
type
human
type
interferon
protein
help
regul
activ
immun
system
ifna
produc
leukocyt
shown
mainli
involv
innat
immun
respons
viral
infect
type
human
type
interferon
protein
produc
larg
quantiti
fibroblast
ifnb
display
antivir
activ
innat
immun
respons
ifng
type
ii
interferon
ifng
cytokin
requir
innat
adapt
immun
viral
bacteri
protozo
infect
ifng
shown
import
activ
macrophag
induc
class
ii
major
histocompat
complex
molecul
express
ifng
produc
predominantli
natur
killer
nk
nk
cell
part
innat
immun
respons
h
cytotox
tlymphocyt
effector
cell
antigenspecif
immun
develop
recent
classifi
type
iii
interferon
group
consist
molecul
call
also
call
respect
cytokin
come
isoform
play
role
innat
immun
defens
virus
highli
similar
amino
acid
sequenc
shown
exhibit
antivir
qualiti
inhibit
tumor
cell
prolifer
promot
antitumor
immun
respons
potent
antivir
cytokin
upregul
mhc
class
express
cell
surfac
h
cell
subsequ
produc
addit
posit
feedback
loop
ligand
receptor
also
bind
contribut
mani
overlap
function
major
matur
differenti
cytokin
express
h
cell
eosinophil
mice
human
subject
shown
play
instrument
role
eosinophil
inflamm
patient
allerg
diseas
cytokin
also
known
implic
wide
varieti
inflammationassoci
diseas
state
associ
matur
b
cell
shown
act
endogen
pyrogen
capabl
induc
fever
patient
autoimmun
diseas
infect
cytokin
produc
primarili
h
cell
involv
sever
stage
bcell
matur
differenti
critic
pathogenesi
allergeninduc
asthma
oper
mechan
independ
ige
eosinophil
proinflammatori
cytokin
share
sequenc
similar
shown
favor
h
immun
respons
activ
dendrit
cell
innat
lymphoid
cell
member
famili
cytokin
potent
drive
product
h
cytokin
produc
epitheli
cell
activ
h
cell
interferon
regulatori
factor
irf
member
irf
factor
famili
play
import
role
innat
immun
system
respons
viral
infect
induct
type
interferon
melanoma
differenti
factor
rigilik
receptor
doublestrand
rna
dsrna
helicas
enzym
function
pattern
recognit
receptor
recogn
long
dsrna
sensor
virus
univers
adapt
protein
function
essenti
signal
transduc
tolllik
receptor
tlr
signal
pathway
except
pathway
regul
activ
numer
proinflammatori
gene
includ
transcript
factor
nuclear
factor
kb
retino
acidinduc
gene
rig
rigilik
receptor
doublestrand
rna
dsrna
helicas
enzym
function
pattern
recognit
receptor
short
dsrna
phosphoryl
singlestrand
rna
rigi
sensor
virus
specif
influenza
sendai
viru
flaviviru
result
induct
member
type
interferon
famili
suppressor
cytokin
signal
neg
regul
cytokin
signal
member
statinduc
stat
inhibitor
ssi
famili
express
gene
shown
induc
subset
cytokin
includ
erythropoietin
type
interferon
ifng
neg
regul
cytokin
signal
janu
kinasesign
transduc
activ
transcript
pathway
express
gene
induc
variou
cytokin
includ
ifng
tolllik
receptor
tlr
member
tlr
famili
play
fundament
role
pathogen
recognit
activ
innat
immun
recogn
dsrna
associ
viral
infect
induc
activ
interferon
regulatori
factor
nuclear
factor
kb
tolllik
receptor
tlr
tlr
recogn
singlestrand
rna
ssrna
endosom
common
featur
viral
genom
recogn
ssrna
virus
hiv
hepat
c
viru
gurich
ssrna
tolllik
receptor
tlr
similar
endosom
receptor
recogn
singlestrand
rna
ssrna
recogn
ssrna
virus
influenza
sendai
coxsacki
b
virus
bind
viral
rna
signal
lead
activ
transcript
factor
nuclear
factor
kb
antivir
respons
also
recogn
ssrna
virus
hiv
hcv
editor
wish
acknowledg
kristina
bielewicz
ms
prepar
glossari
asthma
consid
possibl
role
innat
interferon
defici
asthma
incept
detail
respiratori
virus
associ
asthma
includ
virus
caus
common
cold
influenzalik
ill
wheez
bronchiol
children
respiratori
virus
main
trigger
ae
adult
schoolag
children
account
around
virus
associ
ae
includ
respiratori
syncyti
viru
rsv
influenza
virus
human
rhinovirus
coronavirus
parainfluenza
virus
adenovirus
recent
identifi
metapneumovirus
bocavirus
also
involv
howev
less
common
rsv
rhinovirus
associ
asthma
incept
strongli
associ
wheez
infant
howev
exact
mechan
remain
elus
argument
whether
rhinovirus
rsv
caus
asthma
might
marker
asthma
suscept
also
unclear
whether
virus
act
manner
subtli
differ
young
children
rsv
bronchiol
link
increas
allerg
sensit
immun
skew
increas
h
respons
skew
h
respons
might
reflect
way
evad
protect
h
respons
although
relat
topic
thoroughli
discuss
elsewher
main
focu
articl
interest
reader
direct
help
review
respiratori
virus
capabl
infect
bronchial
epithelium
lower
airway
result
local
inflammatori
reaction
character
airway
neutrophilia
attract
lymphocyt
activ
macrophag
damag
integr
bronchial
epithelium
effort
limit
viral
spread
host
cell
also
mount
type
ifnab
type
iii
ifnl
interferon
respons
interferon
antivir
cytokin
made
wide
rang
cell
respons
viral
infect
ligat
variou
pattern
recognit
receptor
prr
type
ifna
ifnb
signal
ifna
receptor
ifnar
complex
wherea
type
iii
ifnl
human
subject
act
receptor
b
chain
receptor
chain
interferon
firstlin
defens
viral
infect
induc
express
distinct
gene
term
interferonstimul
gene
isg
signal
type
type
iii
interferon
receptor
complex
isg
extracellular
protein
h
chemokin
interferoninduc
protein
interferoninduc
tcell
alpha
chemoattract
itac
interferon
ifnb
induc
downstream
ifna
ifnl
isg
intracellular
protein
interfer
thu
attempt
contain
viral
protein
traffick
nucleic
acid
synthesi
virion
assembl
releas
current
number
known
isg
thought
exceed
howev
possibl
cell
typespecif
isg
yet
identifi
rhinoviru
infect
induc
rapid
transcript
type
ifnab
type
iii
ifnl
mrna
howev
interferon
express
remain
part
cell
type
depend
import
signal
pathway
use
rhinoviru
induc
ifnb
ifnl
studi
vitro
mous
model
requir
prr
melanoma
differenti
factor
retino
acidinduc
gene
tolllik
receptor
tlr
transcript
factor
interferon
regulatori
factor
irf
increas
suscept
viral
infect
asthmat
patient
first
report
corn
et
al
studi
asthmat
nonasthmat
cohabit
spous
pair
observ
asthmat
patient
nonasthmat
subject
report
similar
incid
rhinoviru
infect
howev
asthmat
patient
prolong
lower
respiratori
tract
symptom
increas
symptom
sever
wark
et
al
cultur
primari
bronchial
epitheli
cell
hbec
bronchial
brush
allerg
asthmat
adult
nonallerg
nonasthmat
adult
ex
vivo
infect
rhinoviru
treat
ligand
polyinosin
polycytidyl
acid
poli
c
hbec
asthmat
patient
produc
lower
level
ifnb
lower
level
virusinduc
apoptosi
higher
rhinoviru
load
time
proinflammatori
cytokin
level
group
similar
cell
asthmat
patient
produc
normal
level
rhinoviru
replic
pretreat
exogen
ifnb
author
conclud
asthmat
patient
specif
defici
ifnb
product
earlier
studi
observ
impair
ifna
releas
pbmc
asthmat
patient
work
sinc
verifi
studi
expand
includ
cell
type
includ
dendrit
cell
dc
bronchoalveolar
lavag
fluidderiv
macrophag
alveolar
macrophag
am
confirm
pbmc
furthermor
ex
vivo
type
iii
level
bronchoalveolar
lavag
macrophag
asthmat
patient
shown
neg
correl
total
cold
score
chang
lung
function
eosinophilia
marker
inflamm
rhinoviru
infect
vivo
strongli
suggest
ifnl
import
pathogenesi
ae
determin
clinic
outcom
rhinoviru
infect
asthmat
patient
recent
sever
report
confirm
initi
find
includ
impair
interferon
express
children
sever
asthma
work
culmin
first
phase
ii
placebocontrol
clinic
trial
inhal
ifnb
asthma
studi
natur
infect
primari
outcom
chang
asthma
control
questionnair
acq
fev
although
trial
found
benefit
primari
outcom
intenttotreat
popul
asthmat
patient
receiv
activ
treatment
versu
receiv
placebo
benefici
effect
observ
peak
expiratori
flow
p
subpopul
compos
patient
sever
asthma
n
activ
n
placebo
benefit
observ
acq
score
p
peak
expiratori
flow
p
find
support
premis
interferon
product
inde
impair
asthmat
patient
restor
defect
benefici
influenc
clinic
diseas
impair
interferon
respons
seen
patient
atop
asthma
date
like
clinic
import
reason
first
impair
interferon
product
vivo
would
adequ
control
viral
infect
could
lead
greater
prolong
infect
includ
progress
potenti
establish
infect
lower
airway
associ
virusinduc
inflamm
second
impair
interferon
product
might
counterregul
ongo
h
inflamm
thu
contribut
establish
h
inflamm
therebi
increas
diseas
pathogenesi
increas
risk
hospit
discuss
length
next
section
studi
investig
impair
interferon
product
asthmat
patient
agreement
sever
studi
fail
show
differ
interferon
product
cell
asthmat
patient
control
subject
reason
dispar
mostli
concern
studi
primari
hbec
cultur
vitro
sever
week
infect
studi
differ
find
like
due
sever
variabl
includ
differ
viral
strain
use
prepar
cellcultur
method
eg
differ
compon
medium
method
propag
also
recruit
phenotyp
asthmat
subject
includ
asthma
sever
asthma
control
atop
statu
also
exist
differ
strength
evid
phenomena
variou
studi
relev
clinic
find
eosinophilia
atopi
ae
rate
find
studi
descript
level
support
evid
summar
tabl
although
major
studi
use
rhinoviru
test
viru
differ
interferon
express
use
pbmc
atop
asthmat
children
ifna
ifnb
k
impair
interferon
group
identifi
use
cluster
analysi
higher
rate
asthma
bal
bronchoalveolar
lavag
ndv
newcastl
diseas
viru
nec
nasal
epitheli
cell
pdc
plasmacytoid
dendrit
cell
stra
sever
therapyresist
asthma
tec
tracheal
epitheli
cell
tslp
thymic
stromal
lymphopoietin
level
evid
interferon
level
asthmat
donor
significantli
lower
control
subject
defici
interferon
level
relat
clinic
diseas
number
ae
eosinophilia
lung
function
ige
level
atopi
h
marker
higher
viral
load
asthmat
patient
significantli
lower
interferon
level
neg
correl
higher
viral
load
asthmat
patient
ifnb
restor
antivir
respons
kother
noninterferon
cytokin
significantli
differ
asthmat
donor
control
subject
virus
produc
mix
result
newcastl
diseas
viru
rsv
use
show
differ
interferon
level
group
studi
pbmc
howev
recent
sidebysid
comparison
interferon
respons
asthmat
patient
control
subject
rsv
influenza
viru
show
impair
interferon
product
hbec
asthmat
patient
anoth
studi
differ
ifna
respons
plasmacytoid
dendrit
cell
also
shown
influenza
viru
studi
comparison
rhinoviru
respiratori
virus
clearli
need
perform
better
understand
whether
defect
interferon
express
viru
specif
likewis
studi
impair
interferon
product
nasal
epitheli
cell
asthmat
patient
produc
mix
result
suggest
defici
might
profound
lower
airway
cell
yet
defici
still
observ
peripher
leukocyt
popul
role
atopi
perplex
baraldo
et
al
show
defici
interferon
product
featur
atop
asthmat
nonatop
asthmat
nonasthmat
atop
children
studi
focus
allerg
rhiniti
without
asthma
produc
mix
result
further
debat
whether
asthma
atopi
drive
defect
argu
controversi
regard
interferon
defici
asthmat
patient
studi
investig
interferon
respons
patient
stabl
diseas
ae
vivo
find
increas
rather
decreas
interferon
level
asthmat
patient
howev
would
argu
studi
interferon
level
vivo
confound
differ
viral
load
one
wish
investig
presenc
interferon
defici
diseas
state
done
infect
cell
standard
quantiti
viru
ex
vivo
stimul
cell
standard
quantiti
viral
mimic
ex
vivo
howev
enhanc
rhinoviru
replic
asthmat
patient
vivo
experiment
challeng
studi
observ
gap
knowledg
relat
argument
impair
interferon
product
asthmat
patient
includ
lack
studi
test
whether
defect
stabl
repeat
sampl
data
asthma
phenotyp
atop
asthma
pauciti
studi
virus
rhinoviru
rhinoviru
versu
comparison
virus
lack
studi
relat
interferon
defici
either
asthma
control
time
sampl
taken
underli
asthma
sever
anoth
limit
ex
vivo
studi
use
small
patient
number
definit
studi
interferon
express
larger
studi
birth
cohort
studi
begin
appli
impair
antivir
immun
taken
consider
note
recent
larg
birth
cohort
studi
identifi
popul
asthmat
patient
impair
interferon
respons
rhinoviru
age
year
use
cluster
analysi
group
increas
wheez
infanc
asthma
adolesc
increas
ae
rate
allerg
sensit
infanc
convers
subgroup
children
low
preval
asthma
also
identifi
group
robust
interferon
respons
antivir
immun
overal
data
strongli
suggest
least
subgroup
asthmat
patient
exist
impair
interferon
antivir
immun
howev
possibl
although
current
unclear
whether
asthmat
patient
impair
interferon
product
new
separ
endophenotyp
import
subgroup
exist
endophenotyp
despit
differ
studi
design
conflict
natur
find
limit
number
studi
support
origin
work
bufe
et
al
wark
et
al
continu
grow
number
approxim
tabl
mechanist
understand
impair
interferon
respons
asthmat
patient
remain
poor
despit
much
effort
inabl
identifi
detail
mechan
like
point
complex
mechan
easili
understood
initi
research
consid
possibl
explan
first
impair
interferon
product
asthmat
patient
due
singl
gene
defect
microrna
epigenet
determin
present
asthmat
patient
hypothesi
would
describ
defect
static
unchang
like
identifi
genomewid
associ
studi
gwass
perhap
larg
gene
express
data
set
nextgener
sequenc
approach
protein
activ
data
set
second
hypothesi
describ
complex
geneenviron
interact
could
involv
variabl
even
transient
phenotyp
immun
imprint
action
gene
microrna
epigenet
determin
thu
far
databas
nextgener
sequenc
microarray
data
gener
fail
show
reproduc
singl
gene
defect
would
explain
specif
decreas
express
innat
interferon
observ
asthmat
patient
except
highaffin
receptor
ige
chain
larg
publish
gwa
data
set
asthma
show
obviou
clue
explain
find
possibl
still
exist
singl
gene
defect
resid
specif
subpopul
asthmat
patient
dilut
larger
studi
defin
asthma
base
clinic
attribut
fev
alon
often
involv
sever
hundr
donor
consid
differ
cell
type
involv
leukocyt
vs
structur
cell
possibl
mechan
respons
defect
cell
type
specif
also
possibl
hbec
cultur
associ
studi
prone
lose
defect
explain
conflict
studi
arisen
consid
avail
evid
coupl
failur
sever
hbec
studi
reproduc
defect
overal
data
argu
singl
genehypothesi
encourag
altern
hypothes
consid
two
studi
identifi
suppressor
cytokin
signal
soc
neg
regul
type
type
ii
interferon
signal
potenti
import
determin
impair
interferon
asthmat
patient
express
cell
airway
smooth
muscl
link
previous
asthma
howev
studi
airway
epitheli
cell
effect
viral
respons
hbec
rhinoviru
infect
h
cytokin
proinflammatori
cytokin
induc
mrna
protein
timedepend
manner
close
relat
famili
member
observ
greater
abund
bronchial
biopsi
specimen
patient
atop
asthma
abund
relat
pc
data
atopi
small
cohort
asthmat
children
sever
therapyresist
asthma
level
mrna
unstimul
cell
neg
correl
impair
ifnb
ifnl
express
rhinoviru
infect
poli
c
treatment
also
function
nuclear
protein
conserv
j
allergi
clin
immunol
volum
number
nuclear
local
sequenc
might
interfer
gene
transcript
bronchial
biopsi
specimen
nuclear
stain
increas
asthmat
patient
function
studi
vitro
mutant
lack
abil
home
nucleu
suppress
rhinovirusinduc
ifnb
induct
data
strongli
suggest
viru
h
cytokineinduc
neg
regul
overexpress
asthmat
patient
might
least
part
respons
impair
interferon
level
observ
studi
requir
support
find
includ
bigger
studi
express
bronchial
epithelium
asthmat
patient
recent
studi
show
reduc
mrna
express
bronchial
biopsi
specimen
patient
sever
asthma
compar
patient
mildtomoder
asthma
howev
immunostain
perform
idea
increas
express
asthmat
patient
remain
attract
provid
mechanist
link
h
pathway
neg
regul
innat
interferon
studi
purifi
am
patient
sever
asthma
rupani
et
al
observ
impair
express
level
reduc
rhinoviru
ligandinduc
ifnb
ifna
mrna
protein
level
howev
express
prr
retino
acidinduc
gene
melanoma
differenti
factor
impair
singlestrand
rna
receptor
use
adaptor
protein
myeloid
differenti
primari
respons
engag
signal
apparatu
lead
activ
henc
ifna
transcript
furthermor
express
invers
relat
ae
rate
acq
score
strongli
suggest
express
level
relat
clinic
asthma
outcom
studi
express
pattern
microrna
identifi
sever
microrna
differ
am
healthi
subject
asthmat
patient
show
ident
untransl
region
express
analysi
identifi
microrna
significantli
upregul
am
asthmat
patient
versu
control
subject
microrna
induc
h
cytokin
proinflammatori
cytokin
tnf
also
ifng
affect
steroid
treatment
import
microrna
reduc
express
shown
use
luciferas
report
target
microrna
result
significantli
increas
interferon
level
isg
induct
togeth
data
offer
import
mechanist
explan
impair
interferon
am
asthmat
patient
decreas
abund
import
prr
due
increas
express
microrna
target
mrna
although
articl
discuss
microrna
increas
abund
asthmat
patient
microrna
repres
new
therapeut
target
aim
restor
defect
antivir
immun
rhinoviru
signific
appreci
studi
also
hatchwel
et
al
identifi
reduc
express
asthmat
patient
endobronchi
biopsi
specimen
relat
impair
mrna
level
work
mous
model
show
downregul
specif
stain
endobronchi
biopsi
specimen
invers
relat
sputum
eosinophil
level
togeth
studi
suggest
leukocyt
express
function
might
key
factor
determin
impair
interferon
product
asthmat
patient
although
studi
show
clearli
import
role
viru
sens
am
lead
innat
interferon
induct
role
h
pathway
remain
incomplet
resolv
h
cytokin
well
establish
effector
molecul
patient
atop
asthma
role
well
describ
elsewher
evid
synergi
viral
infect
allergen
sensit
exposur
first
identifi
epidemiolog
studi
evid
extend
human
challeng
studi
mous
model
rhinoviru
rsv
sever
studi
mice
shown
prior
exposur
rsv
g
protein
lead
strong
h
respons
airway
eosinophilia
infect
furthermor
mice
sensit
ovalbumin
airway
rout
rsv
infect
increas
airway
respons
lung
eosinophilia
associ
h
cytokin
notabl
asthmat
patient
rhinoviru
infect
bronchial
epithelium
also
like
addit
synergist
effect
allergen
sensit
challeng
import
ae
pathogenesi
howev
detail
mechanist
insight
process
complet
discoveri
import
prot
h
factor
thymic
stromal
lymphopoietin
produc
epithelium
induc
type
innat
lymphoid
cell
allow
precis
understand
respiratori
virus
promot
h
pathway
mediat
induc
viral
infect
express
consist
clinic
manifest
asthma
asthma
sever
featur
ae
pathogenesi
virus
induc
prot
h
factor
epithelium
relat
establish
h
immun
depict
fig
studi
yet
link
impair
interferon
respons
known
asthma
phenotyp
howev
studi
observ
phenomena
date
patient
atop
asthma
past
sputum
eosinophil
count
relat
ae
risk
impair
ifnl
cultur
cell
neg
correl
sputum
eosinophilia
serum
ige
stain
level
biopsi
specimen
mechanist
much
evid
show
definit
type
iii
interferon
h
cytokin
exhibit
potent
neg
regul
express
action
ifna
agonist
suppress
h
cell
polar
pure
tcell
mix
leukocyt
cultur
system
downregul
level
pbmc
atop
children
ifna
downregul
mrna
level
unstimul
cell
highlight
neg
regulatori
capac
ifna
express
experi
ifna
increas
chain
express
g
chain
involv
stabil
cell
surfac
togeth
suggest
complex
role
ifna
regul
atopi
igemedi
respons
fact
viral
induct
ifna
earli
life
thought
enhanc
express
dc
antigenpres
cell
like
lead
enhanc
allerg
sensit
suggest
anoth
potenti
mechan
virus
contribut
establish
atopi
mous
model
also
abl
replic
neg
regul
h
respons
administ
airway
suppress
gener
allerg
airway
inflamm
ovalbumin
sensit
challeng
model
mice
h
driven
mechan
involv
downregul
ligand
dc
lead
less
h
cell
polar
recent
mous
model
influenza
viru
infect
infect
mice
result
higher
level
virusinduc
lung
eosinophilia
recruit
higher
level
serum
ige
compar
human
studi
cultur
produc
h
cytokin
downregul
presenc
ifnb
first
studi
show
similar
manner
h
cell
innat
lymphoid
cell
also
affect
innat
interferon
type
function
might
increas
environ
lack
interferon
henc
import
neg
regulatori
mechan
mechan
shown
fig
convers
ex
vivo
mous
model
evid
strongli
suggest
h
pathway
potent
neg
effect
induct
innat
interferon
virus
exampl
crosslink
dc
influenza
viru
rhinoviru
challeng
downregul
ifna
product
block
ige
function
omalizumab
restor
defect
reduc
rate
ae
show
first
time
outsid
experiment
infect
set
ex
vivo
interferon
measur
predict
clinic
outcom
mous
model
pneumoviru
infect
cockroach
allergen
exposur
earli
life
follow
infect
led
asthmalik
phenotyp
impair
lung
type
type
iii
interferon
product
ex
vivo
cultur
plasmacytoid
dendrit
cell
pretreat
show
reduc
ifna
level
infect
along
reduc
level
viperin
receptorassoci
kinas
import
signal
molecul
function
data
support
import
express
function
impair
interferon
product
immun
cell
hbec
pretreat
tgfb
reduc
rhinovirusinduc
ifnb
andor
ifnl
level
suppress
specif
interferon
inhibit
proinflammatori
cytokin
consist
studi
impair
interferon
product
hbec
addit
nont
h
cytokin
inhibitori
effect
interferon
highlight
uniqu
relationship
h
cytokin
innat
interferon
simpli
effect
cytokin
impair
effect
anoth
although
mechan
studi
possibl
relat
induc
h
induc
level
increas
asthmat
patient
potent
neg
regul
virusinduc
interferon
product
therefor
establish
h
cytokin
impair
virusinduc
interferon
prioriti
mechan
could
import
therapeut
target
summari
mechan
respons
h
pathway
impair
innat
interferon
product
shown
fig
overal
evid
strongli
underscor
mani
potenti
mechan
counterregul
h
cytokin
type
iii
interferon
could
propos
patient
atop
eosinophil
asthma
impair
interferon
product
due
ongo
uncontrol
h
inflamm
observ
increas
level
biopsi
specimen
asthmat
patient
directli
suppress
interferon
induct
suggest
mechan
explain
interferon
level
ex
vivo
invers
associ
marker
h
pathway
howev
possibl
impair
interferon
product
might
limit
strictli
patient
eosinophil
h
asthma
mechan
could
explain
impair
interferon
express
asthmat
patient
consid
evid
impair
interferon
product
asthmat
patient
associ
atop
asthma
grow
wealth
studi
use
antit
h
biolog
idea
testabl
hypothesi
futur
research
endeavor
examin
effect
h
biolog
clinic
trial
interferon
express
asthmat
patient
vivo
new
gener
antit
h
biolog
shown
impress
efficaci
reduc
rate
ae
number
studi
differ
biolog
small
molecul
current
undergo
clinic
trial
summar
tabl
ii
target
mab
lebrikizumab
produc
improv
ae
rate
subset
periostinhigh
asthmat
patient
hight
h
subgroup
rate
protocoldefin
exacerb
lower
lebrikizumab
group
placebo
group
p
dupilumab
mab
specif
receptor
chain
reduc
ae
rate
studi
patient
moderatetosever
asthma
eosinophilia
mepolizumab
antibodi
reduc
blood
sputum
eosinophil
number
studi
focus
prednisolonetak
asthmat
patient
persist
sputum
eosinophilia
mepolizumab
also
significantli
reduc
rate
ae
prednisolon
use
improv
median
time
ae
week
anoth
studi
patient
eosinophil
asthma
histori
sever
ae
mepolizumab
significantli
reduc
ae
rate
versu
placebo
receptor
antibodi
benralizumab
significantli
reduc
rate
ae
asthmat
patient
high
baselin
level
eosinophil
furthermor
reslizumab
anoth
antibodi
show
reduct
ae
rate
signific
versu
placebo
patient
poorli
control
eosinophil
asthma
pitrakinra
variant
inhibit
signal
reduc
decreas
fev
versu
placebo
allergen
challeng
atop
asthmat
patient
small
molecul
target
chemoattract
receptorhomolog
molecul
express
h
cell
addit
shown
promis
increas
fev
reduc
eosinophil
airway
inflamm
dnazymetarget
improv
fev
reduc
sputum
eosinophil
number
plasma
level
versu
placebo
patient
eosinophil
asthma
result
encourag
show
proof
concept
target
h
pathway
atop
asthmat
patient
asthmat
patient
eosinophilia
lead
improv
ae
target
ige
also
shown
effect
studi
children
young
adult
persist
asthma
omalizumab
significantli
reduc
proport
particip
exacerb
also
reduc
number
day
asthma
symptom
anoth
studi
asthmat
children
investig
effect
omalizumab
ae
rate
omalizumab
found
improv
ae
rate
approxim
ifna
rhinovirusinfect
pbmc
cultur
also
sampl
omalizumab
treatment
month
although
differ
omalizumab
placebo
treatment
commenc
random
omalizumab
group
improv
ifna
induct
rhinoviru
infect
increas
relat
ae
rate
base
median
ifna
product
omalizumab
group
subject
ifna
level
less
median
almost
increas
ae
rate
compar
display
higher
median
ifna
respons
observ
import
first
evid
measur
ifna
respons
ex
vivo
predict
clinic
outcom
clinic
trial
provoc
suggest
benefit
antit
h
pathway
treatment
might
due
restor
impair
interferon
respons
increas
antivir
immun
consid
number
studi
investig
innat
interferon
respons
asthmat
patient
interferon
therapi
asthma
renew
appreci
antit
h
pathway
biolog
therapeut
intervent
provid
time
summari
offer
import
insight
might
help
explain
current
state
field
like
follow
futur
studi
increas
viral
replic
accompani
impair
interferon
product
lung
cell
asthmat
patient
first
observ
sinc
number
studi
repeat
initi
observ
although
observ
work
culmin
first
trial
inhal
ifnb
asthma
show
signific
effect
subpopul
sever
diseas
although
import
impair
interferon
product
asthmat
patient
remain
contenti
benefit
interferon
therapi
need
confirm
number
import
discuss
point
made
studi
inconsist
studi
investig
interferon
level
asthmat
patient
like
due
subtl
differ
laboratori
techniqu
includ
prepar
use
virus
cell
well
patient
recruit
character
furthermor
phenotyp
hbec
might
unstabl
pauciti
studi
measur
interferon
level
ex
vivo
studi
teach
et
al
shown
possibl
meaning
point
futur
investig
inhal
ifnb
could
benefit
identifi
impair
interferon
respons
prefer
studi
popul
howev
whether
stabl
phenotyp
remain
unprov
identif
microrna
control
express
remain
interest
requir
confirm
role
determin
interferon
induct
immun
cell
also
encourag
tempt
specul
dedic
gwa
poor
interferon
respond
versu
good
respond
might
worthwhil
pursuit
although
effect
ige
crosslink
virusinduc
interferon
regard
antit
h
biolog
propos
herein
benefit
therapi
ae
larg
viral
caus
could
restor
defect
antivir
immun
thu
protect
host
sever
infect
progress
lower
airway
ex
vivo
studi
mous
model
clinic
trial
provid
conclus
evid
type
iii
innat
interferon
h
pathway
antagonist
effect
provid
mechan
mechan
explain
asthmat
patient
might
benefit
h
therapi
restor
defect
innat
interferon
respons
could
novel
mechan
action
futur
studi
biolog
endeavor
examin
detail
testabl
hypothesi
howev
without
conclus
human
evid
link
interferon
respons
aerel
clinic
outcom
novel
hypothesi
remain
underappreci
